Literature DB >> 21248153

Characterization of infecting strains and superantigen-neutralizing antibodies in Staphylococcus aureus bacteremia.

Dorothee Grumann1, Eeva Ruotsalainen, Julia Kolata, Pentti Kuusela, Asko Järvinen, Vesa P Kontinen, Barbara M Bröker, Silva Holtfreter.   

Abstract

Staphylococcus aureus superantigens (SAgs) are highly potent T cell mitogens. Antibodies against non-enterotoxin gene cluster (non-egc) SAgs are common in healthy adults, whereas neutralizing antibodies against egc SAgs are rare. We investigated the infecting S. aureus strains and the anti-SAg antibody response during S. aureus bacteremia (SAB). This prospective clinical study (www.clinicaltrials.gov, NCT00548002) included 43 injection drug users (IDUs) and 44 group-matched nonaddicts with SAB. spa genotypes and SAg gene patterns (multiplex PCR) of the S. aureus isolates were determined. The neutralizing capacities of sera obtained at the acute phase and the convalescent phase of SAB were tested against the SAg cocktail of the respective infecting strain and a panel of recombinant SAgs. The lineages CC59 and CC30 were more prevalent among bacteremia strains from IDUs than among strains from nonaddicts. SAg gene patterns in isolates from IDUs and nonaddicts were similar. At the acute phase of bacteremia, IDUs had more neutralizing antibodies against non-egc SAgs than did nonaddicts. Antibody titers frequently increased during infection. In contrast, there were no neutralizing antibodies against egc SAgs at disease onset and such antibodies were not induced by SAB. SAB triggers an antibody response only against non-egc SAgs. Preimmunization in IDU patients is probably due to previous exposure to the infecting strain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248153      PMCID: PMC3067380          DOI: 10.1128/CVI.00329-10

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  48 in total

Review 1.  Toxic shock syndrome and bacterial superantigens: an update.

Authors:  J K McCormick; J M Yarwood; P M Schlievert
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

2.  Immune cell activation by enterotoxin gene cluster (egc)-encoded and non-egc superantigens from Staphylococcus aureus.

Authors:  Dorothee Grumann; Sandra S Scharf; Silva Holtfreter; Christian Kohler; Leif Steil; Susanne Engelmann; Michael Hecker; Uwe Völker; Barbara M Bröker
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease.

Authors:  Sophie Jarraud; Christophe Mougel; Jean Thioulouse; Gerard Lina; Hélène Meugnier; Françoise Forey; Xavier Nesme; Jerome Etienne; François Vandenesch
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Association of recurrent furunculosis with Panton-Valentine leukocidin and the genetic background of Staphylococcus aureus.

Authors:  Helena Masiuk; Katarzyna Kopron; Dorothee Grumann; Christiane Goerke; Julia Kolata; Joanna Jursa-Kulesza; Stefania Giedrys-Kalemba; Barbara M Bröker; Silva Holtfreter
Journal:  J Clin Microbiol       Date:  2010-03-03       Impact factor: 5.948

5.  egc, a highly prevalent operon of enterotoxin gene, forms a putative nursery of superantigens in Staphylococcus aureus.

Authors:  S Jarraud; M A Peyrat; A Lim; A Tristan; M Bes; C Mougel; J Etienne; F Vandenesch; M Bonneville; G Lina
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

6.  The population structure of Staphylococcus aureus among general practice patients from The Netherlands.

Authors:  G A Donker; R H Deurenberg; C Driessen; S Sebastian; S Nys; E E Stobberingh
Journal:  Clin Microbiol Infect       Date:  2009-01-28       Impact factor: 8.067

7.  Molecular epidemiology of Staphylococcus aureus in asymptomatic carriers.

Authors:  S Monecke; C Luedicke; P Slickers; R Ehricht
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-05-12       Impact factor: 3.267

8.  Methicillin-sensitive Staphylococcus aureus bacteraemia and endocarditis among injection drug users and nonaddicts: host factors, microbiological and serological characteristics.

Authors:  Eeva Ruotsalainen; Minna Kardén-Lilja; Pentti Kuusela; Jaana Vuopio-Varkila; Anni Virolainen-Julkunen; Seppo Sarna; Ville Valtonen; Asko Järvinen
Journal:  J Infect       Date:  2008-03-07       Impact factor: 6.072

9.  Reclassification of Staphylococcus aureus nasal carriage types.

Authors:  Alex van Belkum; Nelianne J Verkaik; Corné P de Vogel; Hélène A Boelens; Jeroen Verveer; Jan L Nouwen; Henri A Verbrugh; Heiman F L Wertheim
Journal:  J Infect Dis       Date:  2009-06-15       Impact factor: 5.226

10.  Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus.

Authors:  Nelianne J Verkaik; Corné P de Vogel; Hélène A Boelens; Dorothee Grumann; Theo Hoogenboezem; Cornelis Vink; Herbert Hooijkaas; Timothy J Foster; Henri A Verbrugh; Alex van Belkum; Willem J B van Wamel
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

View more
  19 in total

Review 1.  The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.

Authors:  Gordon Y C Cheung; Michael Otto
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

2.  Predictors of colonization with Staphylococcus species among patients scheduled for cardiac and orthopedic interventions at tertiary care hospitals in north-eastern Germany-a prevalence screening study.

Authors:  S Neidhart; S Zaatreh; A Klinder; S Redanz; R Spitzmüller; S Holtfreter; P Warnke; A Alozie; V Henck; A Göhler; M Ellenrieder; M AbouKoura; D Divchev; D Gümbel; M Napp; G Steinhoff; C Nienaber; A Ekkernkamp; W Mittelmeier; C Güthoff; A Podbielski; D Stengel; R Bader
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-21       Impact factor: 3.267

3.  Expression of staphylococcal superantigens during nasal colonization is not sufficient to induce a systemic neutralizing antibody response in humans.

Authors:  M Burian; D Grumann; S Holtfreter; C Wolz; C Goerke; B M Bröker
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-31       Impact factor: 3.267

Review 4.  Where does a Staphylococcus aureus vaccine stand?

Authors:  V G Fowler; R A Proctor
Journal:  Clin Microbiol Infect       Date:  2014-05       Impact factor: 8.067

5.  Superantigens subvert the neutrophil response to promote abscess formation and enhance Staphylococcus aureus survival in vivo.

Authors:  Stacey X Xu; Kevin J Gilmore; Peter A Szabo; Joseph J Zeppa; Miren L Baroja; S M Mansour Haeryfar; John K McCormick
Journal:  Infect Immun       Date:  2014-06-09       Impact factor: 3.441

6.  Humoral immune consequences of Staphylococcus aureus ST239-associated bacteremia.

Authors:  H Ghasemzadeh-Moghaddam; Wjb van Wamel; A van Belkum; R A Hamat; M Tavakol; V K Neela
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-04       Impact factor: 3.267

Review 7.  Fighting Staphylococcus aureus Biofilms with Monoclonal Antibodies.

Authors:  Dina Raafat; Michael Otto; Kevin Reppschläger; Jawad Iqbal; Silva Holtfreter
Journal:  Trends Microbiol       Date:  2019-01-19       Impact factor: 17.079

8.  Prevalence of Toxin Genes among the Clinical Isolates of Staphylococcus aureus and its Clinical Impact.

Authors:  Divya Deodhar; George Varghese; Veeraraghavan Balaji; James John; Grace Rebekah; Jeshina Janardhanan; Ranjith Jeyaraman; Sudha Jasmine; Prasad Mathews
Journal:  J Glob Infect Dis       Date:  2015 Jul-Sep

Review 9.  PI3K/Akt/mTOR, a pathway less recognized for staphylococcal superantigen-induced toxicity.

Authors:  Teresa Krakauer
Journal:  Toxins (Basel)       Date:  2012-11-15       Impact factor: 4.546

Review 10.  Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions.

Authors:  Teresa Krakauer
Journal:  Toxins (Basel)       Date:  2013-09-24       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.